Physician profile
Nicolas Thomas
NPI 1235892431
$1,622.57
in general payments reported to CMS, 2019-2025
15 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $20.03 · 2022: $413 · 2023: $304 · 2024: $514 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,189.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $433.11 | 2022-2025 | Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $338.79 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $325.06 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $141.99 | 2022-2025 | Otezla, Repatha, Repatha |
| Lilly USA, LLC | $110.50 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Novartis Pharmaceuticals Corporation | $48.49 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.37 | 2022-2024 | Tradjenta, Jardiance |
| Dexcom, INC. | $40.36 | 2023 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $32.61 | 2024-2025 | Voquezna |
| Baudax Bio INC. | $22.32 | 2022 | |
| Pfizer INC. | $19.91 | 2025 | |
| Genentech USA, INC. | $19.45 | 2023 | Venclexta |
| Daiichi Sankyo INC. | $16.48 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.63 | 2025 | Fanapt |
| Bayer Healthcare Pharmaceuticals INC. | $14.50 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolas Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.